Proteomic identification and profiling of canine lymphoma patients

Veterinary and Comparative Oncology

Volumn 7, Issue 2, 2009, Pages 92-105

  Ratcliffe, L ^a   Mian, S ^a   Slater, K ^a   King, H ^a   Napolitano, M ^b   Aucoin, D ^b   Mobasheri, Ali ^c  

^a BioCity   (United Kingdom)

^b ANTECH DIAGNOSTICS   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bioinformatics; Biomarker canine; CART; Lymphoma; Proteomics; SELDI; Serum

Indexed keywords

EID: 65749099746     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00165.x     Document Type: Article

References (24)

1. MacEwen EG. Spontaneous tumors in dogs and cats: Models for study of cancer biology and treatment. Cancer Metastasis Reviews 1990; 9: 125-136.
2. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RJ, Springer DL and Pounds JG. Toward a human blood serum proteome: Analysis by multidimensional separation coupled with mass spectrometry. Molecular & Cellular Proteomics 2002; 1: 947-955.
3. Vail DM and McEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000; 18: 781-792.
4. Espina V, Dettloff KA, Cowherd S, Petricoin EF III and Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. Expert Opinion on Biological Therapy 2004; 11: 83-93.
5. Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, McCardle S, Ellis IO, Creaser C, et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002; 18: 395-404.
6. Mian S, Ball G, Hornbuckle J, Holding F, Carmichael J, Ellis I, Ali S, Li G, McArdle S, Creaser C, et al. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 2003; 3: 1725-1737.
7. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R and Schadendorf D. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. Journal of Clinical Oncology 2005; 23: 5088-5093.
8. Antuofermo E, Miller MA, Pinino S, Xie J, Badve S and Mohammed SI. Spontaneous mammary intraepithelial lesions in dogs -a model of breast cancer. Cancer Epidemiology, Biomarkers & Prevention 2007; 16: 2247-2256.
9. Cadieu E and Ostrander EA. Canine genetics offers new mechanisms for the study of human cancer. Cancer Epidemiology, Biomarkers & Prevention 2007; 16: 2181-2183.
10. Sasaki K, Sato K, Akiyama Y, Yanagihara K, Oka M and Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Research 2002; 62: 4894-4898.
11. Grossklaus DJ, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumour involvement in the radical prostatectomy specimen among men with an elevated PSA. Urologic Oncology 2002; 7: 195-198.
12. Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusarco VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC and Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
13. Rai AJ, Zhang Z, Rosenweig J, Shih le M, Pham T, Fung ET, Sokoll LJ, Chan DW. Proteomic approaches to tumor marker discovery. Archives of Pathology & Laboratory Medicine 2002; 126: 1518-1526.
14. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer YY, Feng Z and Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 2002; 62: 3609-3614.
15. Petricoin EF III, Ornstein DK, Pawletez CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC and Liotta LA. Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute 2002; 94: 1576-1578.
16. Lancashire LJ, Mian S, Ellis IO, Rees RC and Ball G. Current developments in the analysis of proteomic data: Artificial neural network data mining techniques for the identification of proteomic biomarkers related to breast cancer. Proteomics 2005; 2: 15-29.
17. Tanaka K, Waaki H, Ido H, Akita S and Yoshida T. Protein and polymer analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry 1988; 2: 151-153.
18. Karas M and Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10 000 daltons. Analytical Chemistry 1988; 60: 2299-2301.
19. Merchant M and Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight mass spectrometry. Electrophoresis 2001; 21: 1164-1174.
20. Anderson NL and Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Molecular & Cellular Proteomics 2002; 1: 845-867.
21. Oh JH, Nandi A, Gurnani P, Knowles L, Schorge J, Rosenblatt KP and Gao JX. Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. Journal of Bioinformatics and Computational Biology 2006; 4: 1159-1179.
22. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, van Haaften-Day C, Hacker NF, de Bruijn H, van der Zee A, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research 2004; 64: 5882-5890.
23. Tan CS, Ploner A, Quandt A, Lehtio J, Pernemalm M, Lewensohn R and Pawitan Y. Annotated regions of significance of SELDI-TOF-MS spectra for detecting protein biomarkers. Proteomics 2006; 6: 6124-6133.
24. McCaw DL, Chan AS, Stegner AL, Mooney B, Bryan JN, Turnquist SE, Henry CJ, Alexander H and Alexander S. Proteomics of canine lymphoma identifies potential cancer-specific protein markers. Clinical Cancer Research 2007; 13: 2496-2502.